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Abstract: RNA in cells is always associated with RNA-binding proteins that regulate all aspects
of RNA metabolism including RNA splicing, export from the nucleus, RNA localization, mRNA
turn-over as well as translation. Given their diverse functions, cells express a variety of RNA-binding
proteins, which play important roles in the pathologies of a number of diseases. In this review we
focus on the effect of alcohol on different RNA-binding proteins and their possible contribution to
alcohol-related disorders, and discuss the role of these proteins in the development of neurological
diseases and cancer. We further discuss the conventional methods and newer techniques that are
employed to identify RNA-binding proteins.
Keywords: RNA-binding proteins; mRNA stability; mRNA splicing; gene expression; alcohol;
neurological diseases; cancer
1. Introduction
In this review we provide a succinct overview of the role of RNA-binding proteins (RBPs) in
regulating gene expression. Our summary is by no means exhaustive but is meant to give a flavor
of the repertoire of RBPs recognized as important players in different disease processes. We have
divided the review into subheadings under which we discuss the effect of alcohol on RNA-binding
proteins, RNA-binding proteins in neurological diseases and cancer, and finally the methods employed
to identify RBPs and/or ligands of a RBP.
Gene expression is comprised of a series of well-coordinated events both at the transcriptional
and post-transcriptional level. While we have a fairly good understanding of transcriptional events,
post-transcriptional processes are comparatively far less understood. Transcription takes place in the
nucleus where genes are transcribed from DNA, the blueprint of the cell. The transcribed RNA now
represents information required to direct cellular function to maintain cell homeostasis. Before this
information can be relayed to the cytoplasm, the nascent RNA undergoes extensive post-transcriptional
processing before arriving at its final destination in cells. For this process the RNA is associated with
nuclear proteins that aid in splicing and nuclear export [1]. As mRNA molecules emerge from the
nucleus, bound nuclear proteins are often replaced with a new set of RNA-binding proteins (RBPs).
In fact RBPs are involved in every step of the RNA lifecycle, e.g., transport of mRNA to the site of
translation, storage and mRNA degradation (Figure 1) [1].
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Figure 1. RNA-binding proteins and their role in RNA metabolism: Genomic DNA is 
transcribed in the nucleus resulting in generation of hnRNA. RNA-binding proteins (RBP) 
are involved in (1) splicing and alternative splicing of hnRNA, resulting in the formation of 
mRNAs. Messenger RNAs are then transported from nucleus into the cytoplasm (2). In the 
cytoplasm, RBPs aid in the localization of mRNAs to their final destination site (3). Once in 
the cytoplasm, each mRNA has a specific turn-over rate (4) that can be modulated by 
association with selective RBPs. The turn-over rate of mRNAs in cells can be altered in 
response to intrinsic and extrinsic stimuli. Messenger RNAs serve as a template for 
translation and RBPs play an important role in translation (5). 
Figure 1. RNA-binding proteins and their role in RNA metabolism: Geno ic DNA is transcribed in
the nucleus resulting in generation of hnRNA. RNA-binding proteins (RBP) are involved in (1) splicing
and alternative splicing of hnRNA, resulting in the formation of mRNAs. Messenger RNAs are then
transported from nucleus into the cytoplasm (2). In the cytoplasm, RBPs aid in the localization of
mRNAs to their final destination site (3). Once in the cytoplasm, each mRNA has a specific turn-over
rate (4) that can be modulated by association with selective RBPs. The turn-over rate of mRNAs in cells
can be altered in response to intrinsic and extrinsic stimuli. Messenger RNAs serve as a template for
tran lation and RBPs play an important role in translation (5).
From the diversity of their function it is apparen that these proteins have an important role to play
in most if not all post-transcriptional events. With the advent of high throughput screening techniques
and quantitative proteomics, several hundred potential RBPs have been identified [2,3]. Given this
large number of proteins, every effort is being made to expand our knowledge on RNA-protein
interactions. RNA-binding proteins can be classified according to their pattern of expression and
the type of target RNA. The pattern of RNA-binding protein expression can differentially regulate
gene expression and this in turn can determine the fate of cells during development [4]. Expressions
of target can be dampened or enhanced by RBPs as seen in yeast [5]. There are those proteins that
are ubiquitously expressed and are associated with several different RNAs, while others are less
promiscuous and associate with only a limited number of RNAs in specific cells. Messenger RNAs
bind RBPs through one or more RNA-binding domains (RBDs). These domains are very versatile
in that they can recognize either single or double stranded RNA, specific sequences in the primary
structure of the RNA, or even RNA structures at the three dimensional level [6]. Compared to the large
number of RBPs that have been identified or are predicted to serve as RBPs, relatively few RBDs have
been identified so far although their number is constantly increasing [7]. Some of the RBDs are found
only in a single species, whereas others are evolutionary conserved (for a review on RBDs see [7]).
Most RBPs contain multiple RBDs. This arrangement has several distinct advantages. By utilizing
several RBDs, the protein can recognize much longer stretches of nucleic acids. This scenario would
not be applicable to a RBP harboring a single RBD [8]. Another advantage of having multiple RBDs
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on a single protein is the affinity of RNA-protein interaction. Proteins bind to target RNAs with high
affinity. The presence of multiple RBDs allows for greater binding specificity. This is an important
consideration given the observation that many more RBPs have been identified than RBDs. Multiple
RBDs also make room for protein-protein interactions among RBPs, thereby increasing the stability of
multiple RBPs-RNA complex and RNA-binding specificity of RBPs [8].
In an attempt to organize the expanding data on RBPs, Gerstberger et al. have compiled a census
of human RBP [9]. They identified RBPs if proteins contained domains known to directly interact with
RNA. Using this criterion, 1542 RBPs were manually curated and analyzed for their interaction with
different classes of RNA, their evolutionary conservatism, abundance and tissue-specific expression.
In another study 1344 genes encoding for RBPs in the human genome were catalogued [10]. Because
many RBP lack bona fide RNA-binding motifs, Ray et al. set out to systematically analyze RNA motifs
recognized by a diverse group of RBPs. The results of their study provide an important resource for
post-transcriptional regulatory processes [11].
MicroRNAs (miRNAs) have emerged recently in the landscape of post-transcriptional regulation.
They are considered both friends and foes due to their mode of action. A brief introduction to
microRNAs and their mode of action is provided here. MicroRNAs are short (~22 nucleotides long)
non-coding RNAs that are expressed in a tissue specific manner and bind specifically to target mRNAs.
If RBPs are considered guardians of genetic messengers, then microRNAs may be referred to as “micro”
guards of mRNAs. MicroRNAs control gene expression by the down regulating and fine tuning of
transcripts by translational repression and/or degradation of respective mRNAs [12–14]. Regardless
of the mechanism of miRNA operation, miRNAs hybridize to specific short sequences in the 3'-UTR of
mRNAs [15]. A public repository (http://www.mirbase.org) has been created for all published miRNA
sequences [16]. Since miRNA and mRNA interaction is sequence specific it is hard to predict mRNA
target(s) of a miRNA. To overcome this shortcoming, several groups of researchers have developed
computational methods to identify miRNA target sites in transcripts [17]. As both RBPs and miRNA
associate with sequences in 3'-UTR of mRNAs, the question arises whether these regulators bind to
the same sequence in the 3'-UTRs. Available data shows that some miRNAs compete for the RBP
binding site, while the majority of experimental data suggests that miRNA-binding sites surround
RBP-binding sites in the 3'-UTRs [15,18]. Databases such as starBase (http://starbase.sysu.edu.cn/)
have been developed to identify mRNA-miRNA (+ other non-coding RNAs) and mRNA-protein-RNA
interaction networks [19]. Simultaneous binding of miRNA and RBPs to their respective sequences in
the mRNA can be co-operative where both molecules work in harmony or antagonistically to oppose
their respective functions [14].
2. RNA-Binding Proteins and Alcohol
Alcohol abuse poses a large disease with a high economic and social burden nationwide. In 2006
alcohol-related costs in the United States incurred the country $223.5 billion. Globally, 3.3 million
deaths have been attributed to alcohol use [20]. Alcohol consumption affects many organ systems
in the body and can change the pattern of gene expression both in culture and in animal models.
Such alterations to gene expression are due to the consequences of alcohol’s ability to induce changes
to normal cellular signaling, leading to changes in gene transcription. For instance, transcription
factors and nuclear factors NF-κB and AP-1 are regulated both positively and negatively in pancreatic
acinar cells following alcohol exposure. Such regulation is believed to contribute to ethanol toxicity
in the pancreas [21]. Alcohol also modifies epigenetic landscape in cells, resulting in the modulation
of gene expression [22]. In the central nervous system (CNS), alcohol has a pervasive effect and
affects a number of neurotransmitter and neuromodulator systems. Some of the molecular changes
associated with long-term effects of alcohol exposure are linked to alterations in signaling of the
gene transcription factor, cAMP response element-binding protein (CREB) [23]. The consensus cAMP
response element to which CREB binds has been identified in the promoter region of many genes [24],
thus assigning this transcription factor an important role in the development of alcohol addiction [25].
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While changes in epigenome, gene transcription, phosphorylation and signaling cascades in response
to alcohol exposure have remained a focus of research, studies addressing the effects of alcohol on RBPs
have been comparatively scant. One possible explanation for this difference may be the non-global
cumbersome approaches of the “bygone era” to examine post-transcriptional events in the regulation
of gene expression. We hope that the technological advancements such as CLIP and RNA-seq will
stimulate more investigations in this exciting field of gene transcription. Nevertheless, with the help of
enduring “gold standard” techniques of the “bygone era”, a number of studies have paved the path in
this field. For example, it has been demonstrated that alcohol exposure does affect expression of RBPs,
leading to disruption of molecular pathways in different cells/tissues.
The glutamatergic neurotransmitter system is one major neurotransmitter system that is
affected by alcohol exposure [26]. N-methyl-D-aspartate receptors (NMDA) belong to the family
of glutamatergic receptors and are a well-established target of alcohol. They have been implicated
in the development of alcohol dependence, tolerance, and withdrawal syndrome [27]. NMDA
receptors assemble to form multimeric complexes consisting of different subunits. Molecular cloning
revealed that NMDA receptors are comprised of seven different subunits, which fall into three distinct
subfamilies: the GluN1 subunit, the four distinct GluN2 subunits (GluN2A, GluN2B, GluN2C, GluN2D)
and two GluN3 subunits (GluN3A and GluN3B) [28]. The GluN1 subunit is considered the obligatory
subunit, as functional receptors cannot be formed without it [29]. This subunit is the product of a
single gene and has 8 full-length splice variants [30]. Chronic alcohol exposure induces a number
of adaptive processes in the nervous system, including an upregulation of NMDA receptor number
and function both in vitro and in vivo [31–33] with a concomitant increase in GluN1 and GluN2B
receptor subunit expressions [33,34]. Our laboratory made the seminal observation on the GluN1
mRNA stability in cultured mouse fetal cortical neurons that are chronically exposed to alcohol. We
found that the half-life of GluN1 mRNA increases to more than 24 h [35]. However, when the new
protein synthesis is inhibited by culturing mouse fetal cortical neurons in the presence of the protein
synthesis inhibitor, cycloheximide, the half-life of the GluN1 mRNA returns to control values [36]. This
observation strongly suggested that new protein synthesis is critical to observe the increase in half-life
of GluN1 mRNA. As it is well established that RNA-binding proteins contribute to the regulation of
mRNA half-life [1], our laboratory undertook a systematic study to identify GluN1-mRNA-binding
proteins that may regulate the half-life of GluN1 mRNA. Our investigations revealed a 156 nucleotides
long cis-acting region in the 3'-UTR of GluN1 mRNA, and three RBPs bind to this region. Two of
these RBPs are identified as annexin A2, a known RBP [37], and the second as the β subunit of α
glucosidase II (GIIβ). In agreement with our observation that new protein synthesis is obligatory
for the increase in GluN1 mRNA half-life to occur, we demonstrated that chronic alcohol exposure
increases the expression of GIIβ both in cultured fetal cortical neurons and in the cerebral cortex of
adult mice chronically exposed to alcohol [38,39]. The GIIβ protein is a novel RBP, as it was not known
to bind RNA previously. GIIβ is the non-catalytic subunit of the α-glucosidase II (GII) [40]. GII enzyme
is an ER resident protein, and its subunits alpha and beta are covalently linked [40,41]. The catalytic
activity of the enzyme is conferred by the alpha subunit. The alpha subunit is a soluble protein and
lacks an ER retention signal. It is retained in the ER by its association with the GIIβ subunit (Figure 2).
Alpha glucosidase GII is an important enzyme in chaperone-assisted folding of nascent glycoproteins
in the rough endoplasmic reticulum [40]. The notion that enzymes can serve as RBPs is not unlikely, as
several metabolically active enzymes are known to interact with specific mRNAs [42]. For example, the
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is originally identified as an enzyme
important in glycolysis. However, further studies revealed that this enzyme also plays a role in other
cellular processes [43]. GAPDH interacts with acts colony-stimulating factor-1 mRNA and regulates
its half-life in ovarian cancer cells [44]. A microarray screen for RBPs in yeast revealed that a large
proportion of previously known enzymes also act as RBPs [45]. Multifunctional enzymes are beneficial
to an organism in that they can facilitate communication and/or cooperation between different cellular
functions and pathways within the complex cellular network in cells.
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The second GluN1 mRNA-binding protein, annexin A2 is a known RBP. Annexin A2 belongs
to a large family of proteins that bind anionic phospholipids in a calcium dependent manner and
are important in membrane organization and cytoskeletal interactions [46]. First, demonstration
that annexin A2 is a RBD was documented in 2004. It was shown to bind specifically to c-myc
RNA [47]. Later, it was found to interact with its own mRNA [37]. Binding of annexin A2
to c-myc and its own mRNA occurred via a putative RNA-binding domain consisting of five
nucleotides 5'-AA(C/G)(A/U) [37]. This RNA-binding motif is also present in the 3'-UTR of GluN1
mRNA [39]. It appears that annexin A2 interacts with specific mRNAs translated on cytoskeletal-bound
polysomes [24]. Indeed the GluN1 mRNA is always associated with polysomes. However, the exact
role of annexin A2 as RBP has not been elucidated. It is likely that it is involved in mRNA transport
and localization.
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Figure 2. A proposed mechanism of NR1 mRNA regulation in normal and chro ic etha ol xposed fetal
cortical neurons: The NR1 mRNA is localized in the rough endoplasmic reticulum (RER) irrespective
of ethanol treatment [36]. The normal half-life of NR1 mRNA is ~15 h in cultured fetal cortical
neurons (FCNs). Following chronic ethanol exposure, the half-life of NR1 mRNA increases to
more than 24 h in FCNs [35]. One of the potential mechanisms that can explain increase in NR1
mRNA half-life is increased binding of GIIβ to NR1 mRNA as demonstrated previously by us [38,39].
Decline in ethanol concentration, e.g., ethanol withdrawal in chronic ethanol exposed FCNs, triggers
post-translational modification, e.g., phosphorylation of GIIβ—a process that occurs in normal FCNs
as well. Phosphorylation of GIIβ alters the protein conformation such that GIIβ is no longer bound
to NR1 mRNA. Loss of interaction with GIIβ allows NR1 mRNA to become temporarily “naked”.
Endoribonclease(s) present in the vicinity are now able to attack the NR1 mRNA, eventually leading to
NR1 mRNA degradation.
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Binge drinking refers to consumption of 4–5 drinks* (as ě4 drinks for a woman and ě5 drinks for
a man on a single occasion) within 2 h as per NIH-NIAAA guidelines, and this type of drinking brings
blood alcohol levels to 0.08 g/dL. According to NIH-NIAAA, a standard drink in the US is considered
as 12 ounces of regular beer (about 5% alcohol) or 5 ounces of wine (about 12% alcohol) or 1.5 ounces
of 80-proof distilled spirits (about 40% alcohol) [20]. Binge drinking has become a popular form of
alcohol abuse in the younger population and more recently in the older generation [48]. In younger
individuals, the brain is particularly sensitive to the repeated withdrawals of alcohol resulting from
alternating periods of intoxication and withdrawal. Binge drinking has serious consequences, such as
impairment of the cognitive function [49]. One of the mechanisms proposed for a decline in cognitive
function in binge drinkers is the inflammation of central nervous system [50]. Resident macrophages
in the brain are called microglia, and they constitute a large proportion of cells in the brain. Microglia
perform a number of functions in the context of inflammation and brain injury [51]. Activation of
microglia is considered to be neuroprotective. However, over-activation of microglia results in the
release of neuroinflammatory molecules that subsequently lead to neuronal pathology [52]. Recently,
a protein with a molecular mass of 18 kDa was identified as a candidate protein that could facilitate
alcohol-induced neuroinflammation [39]. The 18 kDa protein is a cold shock protein with an N-terminal
RNA-binding domain. This protein is named as cold inducible RNA-binding protein (CIRP) because its
expression at the mRNA and protein level can be induced within 12 h after lowering the temperature
from 37 ˝C to 32 ˝C [53]. CIRP is involved in a number of cellular processes including transcription,
translation, DNA recombination, and cell proliferation [53]. In most tissues and cell lines, CIRP is
constitutively expressed albeit in low amounts [54]. However, a significant increase in the expression
of CIRP mRNA and protein is noted in the mouse brain after binge alcohol intoxication. Similar
effects of alcohol are observed on CIRP expressions in the cultured murine microglial cell line BV2 [55].
In CIRP knock-out (CIRP´{´) mice, levels of inflammatory molecules such as TNFα and IL-1β are
markedly attenuated as compared to wild type mice following alcohol consumption. Thus, both
in vivo and in vitro studies assign a new function to CIRP of being a proinflammatory molecule that
mediates inflammation in the brain following alcohol consumption [55]. Recent studies show that
CIRP modulates a circadian gene called the Circadian Locomotor Output Cycles Kaput (CLOCK)
expression post-transcriptionally in mammalian tissues [56]. A normal expression of CLOCK genes
is necessary for maintenance of mammalian circadian function. An increased expression of CIRP
following binge drinking can disrupt circadian function, and this may lead to stress and sleep rhythm
disturbances [57].
Alcohol does not only affect the mature brain but also has profound effects on the developing brain.
Maternal alcohol exposure during pregnancy results in a number of abnormalities collectively termed
fetal alcohol syndrome (FAS). At the cellular level, FAS is characterized by neurodegeneration mainly
as a result of apoptosis [58]. In the developing brain, the balance between cell differentiation and
apoptosis is tightly regulated so that the large number of neuronal cells can make proper connections
with other cells and that synaptogenesis can occur in an orderly fashion. The RNA-binding protein,
Napor, which was first identified in the fetal heart [59], is actually involved in apoptosis in the
developing brain as it is highlighted in screens of genes induced during apoptosis in neuroblastoma
cells [60]. Napor is linked to nuclear and cytoplasmic RNA processing events such as alternative
splicing and mRNA stability [61,62]. Using a differential display polymerase chain reaction and RNase
protection assays, Naha et al. observed a reduction in Napor expression in forebrain, midbrain and
hindbrain of fetal rats exposed to alcohol during development [63]. Considering Napor’s role in
programmed cell death, RNA splicing and stability, any alterations in its expression could conceivably
disrupt the formation of correct neuronal connections and cellular homeostasis. Neuronal homeostasis
is critical for normal neuronal development. Therefore, a decrease in Napor may contribute to apoptosis
mediated neurodegeneration—the hallmark of FAS.
Alcohol affects almost all tissues in our body. The liver is another organ that has been examined for
changes in expression of RBPs, as altered expression of RBPs disrupts molecular pathways in different
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cells and tissues. The RBP HuR is a member of the embryonic lethal abnormal vision (ELAV) family
of RBPs originally identified in Drosophila as an essential protein for neural development [64]. HuR
is ubiquitously expressed and plays a role in muscle differentiation and adipogenesis, and promotes
apoptosis [65]. Tumor necrosis factor alpha (TNFα) is a key regulator of the inflammatory response
and is produced mainly by activated macrophages and T-lymphocytes. It is thus not surprising that its
expression is increased in chronic inflammatory diseases such as alcoholism [66]. TNFα expression
is tightly regulated both at the transcriptional and at the post-transcriptional level [67]. HuR is an
important post-transcriptional regulator of TNFα. HuR specifically binds to the AU-rich element
(ARE) located in the 31-UTR of TNFα mRNA in macrophage-like cell line, RAW264.7 [68]. The AU
rich elements located in the 31-UTRs of many mRNAs represent the most common mRNA instability
element [69]. The binding of proteins to ARE protects mRNAs from degradation. Hence ARE-protein
interaction(s) is a pre-requisite for mRNA stability and translation as in the case of TNFα [70]. An
increased expression of TNFα is implicated in the pathogenesis of alcoholic liver disease [71]. The
main reason for associating TNFα with alcoholic liver disease is that TNFα expression is significantly
increased following chronic alcohol exposure in laboratory rodents. Increase in TNFα expression is
caused by lipopolysaccharide (LPS) stimulation of Kupffer cells in liver. Upon LPS stimulation, the
half-life of TNFα mRNA increases due to a binding of HuR to an ARE sequence in the 3'-UTR of TNFα
mRNA [68]. It is also noted that the RNA-binding activity of HuR is increased after the chronic alcohol
exposure of Kupffer cells [72].
Liver disease is a major and debilitating consequence of chronic alcohol consumption. Excessive
alcohol exposure can lead to hepatosteatosis and to more severe consequences such as liver fibrosis
and cirrhosis. How alcohol brings about this effect has been the focus of much investigation.
Galβ1,4GlcNAc-α2,6-sialyltransferase (ST6Gal1) mediates the addition of α2,6-linked sialic acid to
glycoproteins in the Golgi apparatus. It was observed that the mRNA levels of ST6Gal1 are reduced in
post-mortem human livers of moderate and heavy alcohol drinkers. Subsequent studies involving
laboratory rodents showed a significant decline in ST6Gal1 activity accompanied by reduction in
ST6Gal1 mRNA levels following chronic alcohol exposure [73,74]. The importance of this finding lies in
the fact that the reduction in ST6Gal1 enzyme activity causes faulty glycosylation of lipid transporters,
apolipoproteins apoE and apoJ. Improper glycosylation of apolipoproteins apoE and apoJ prompts
perturbations of intracellular lipid transport [75]. This was a compelling reason to further investigate
molecular events causing reduction of ST6Gal1 enzyme activity. The use of techniques such as EMSA
and UV crosslinking were crucial in identifying interaction between 3'-UTR of ST6Gal1 mRNA and
a cytosolic protein with a molecular mass of 41 kDa. The 41 kDa protein was detected in both rat
livers and post-mortem human livers of moderate and heavy alcohol drinkers [74]. The identity of the
41 kDa protein is not known at this time. However, it is believed that 41 kDa cytosolic protein plays a
role in ST6Gal1 mRNA stability as its intracellular concentration decreases following alcohol exposure.
Importantly, the relative intensity of the RNA-protein complex decreases with an increase in alcohol
consumption, suggesting that the 41 kDa RBP associating with the 3'-UTR of ST6Gal1 mRNA is an
alcohol responsive protein.
3. RNA-Binding Proteins in Neurological Diseases
RBPs are ubiquitous partners of RNA and control all aspects of RNA metabolism. Given their
omnipresent nature, dysregulation of RNA processing in a number of pathologies ranging from
neurologic diseases to muscular dystrophies and cancer places them on a higher pedestal. Thus, the
pathologies have become a target of novel therapeutic drugs [76–78]. Among the disorders attributed
to mutations in RBPs, neurologic diseases feature most prominently. One reason why RBPs play such
a prominent role in CNS disorders is because RBPs play a central role in alternative splicing, and this
post-transcriptional regulatory mechanism is most prevalent in the nervous system [79]. In addition,
RBPs are essential to protect mRNAs from premature degradation and translation during their journey
from their site of synthesis in the cell nucleus to cytoplasm, dendrites and axons for de novo protein
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synthesis [80]. These functions of RBPs create vast opportunities for these proteins to contribute to the
pathogenesis of neurological diseases.
Paraneoplastic neurologic disorders (PND) are neurological manifestations resulting from
autoantibodies against two well-known families of RBPs, the Nova and the Hu [81,82]. Family
members of Nova and Hu are expressed ectopically by tumors in breast, lung and/or bladder [65,83,84].
Normally, these members of Nova and Hu are expressed only in the CNS, an immune privileged
environment. However, when they are produced by tumors outside the CNS, they are recognized as
foreign antigens, and an immune response is elicited against their resulting in generation of antibodies.
These antibodies are classified as autoantibodies, as they are produced against an individual’s own
protein. One such example is Paraneoplastic Opsoclonus Myoclonus Ataxia (POMA) [85]. In POMA
patients, autoantibodies are generated as a result of breast, gynecologic, lung and bladder cancers.
These antibodies target a neuron-specific Nova family of RBPs. Nova 1 is expressed primarily in the
hindbrain and spinal cord, while Nova 2 is expressed mainly in the neocortex [86]. At least 34 target
transcripts of Nova are identified using ultraviolet cross-linking and the immunoprecipitation (CLIP)
technique [87]. The majority of Nova targets are involved in neuronal synaptic function, and only
one third of the targets are involved in mediating inhibitory neurotransmission. Nova is important
for alternative splicing of two inhibitory receptor mRNAs in the brain, glycine α2 and GABAA [88].
Gephyrin mRNA that encodes a protein involved in clustering of both GABA and glycine receptors
is also a Nova target [87]. As a consequence of the loss of Nova function, patients diagnosed with
POMA display the dysregulation of inhibitory neurotransmission characterized by an excess of motor
movements. Nova knock-out mice die 7–10 days after birth due to progressive motor dysfunction
coupled with apoptotic cell death in NOVA-expressing brain regions [89]. The Nova knock-out mouse
model was crucial in providing evidence for the importance of Nova in alternative splicing events. In
a clinical setting, patients suffering from POMA have provided us with invaluable insight into the
clinical consequences of Nova dysfunction.
The Hu family members (HuR, HuB, HuC, and HuD) are a second set of RBPs with diverse
functions and mediate antigen-associated immune disorders. Two Hu family members, HuC and
HuD are specifically expressed in the CNS. The Hu family of RBPs regulates half-lives of several
mRNAs by binding to ARE regions in their 3'-UTRs. The binding of Hu family members to mRNAs,
such as epidermal growth factor, cFos and granulocyte-macrophage stimulating factor, results in
stabilization of the respective mRNA [90]. Because of having diverse targets, these RBPs are implicated
in many aspects of neuronal functions. For instance, the inactivation of HuD results in impaired neural
development with motor co-ordination defects in mice [91]. In contrast, overexpression of HuD leads
to abnormal mRNA stabilization associated with cognitive deficits in mice [92]. Diverse neurological
dysfunctions, such as sensory neuropathy, cerebellar ataxia and encephalitis, are exhibited by patients
diagnosed with PND or the anti-Hu syndrome [82]. Molecular mechanisms underlying these diverse
neurological dysfunctions were elucidated by a number of investigators in the field [65]. The majority
of PNDs are associated with small cell lung cancer and gynecologic tumors. These cancer tissues
ectopically express Hu family members such as HuB, HuC and/or HuD. An immune response is
mounted in humans suffering from these cancers. Once the antibodies are generated, they enter the
circulation and subsequently cross the blood-brain barrier. In the brain, these antibodies bind to HuC
and HuD. Bioneutralization of HuC and HuD leads to dysregulation of several mRNAs. This in turn
results in PND-associated neurological dysfunctions including encephalomyelitis and neuropathy [65].
In addition to modulating splicing events and regulating mRNA half-lives, RBPs play important
roles in translational control during embryonic development, cell-cycle progression [93], learning, and
memory formation [94]. Defects in translational control have profound effects on cellular functions
resulting in a multitude of diseases ranging from cancer to autism. A classic example of a consequence
of translational dysfunction is the Fragile X syndrome (FXS), a disease characterized by intellectual
disability, autistic behaviors and childhood seizures [95]. Fragile X syndrome was the first genetic
disorder to link RNA regulation to cognitive function. This syndrome is caused by the absence of the
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RBP, Fragile X mental retardation protein (FMRP). The protein is widely expressed in mammalian
tissues but is particularly abundant in neurons where it can be found in the cell body, proximal
dendrites and axons. FMRP is a component of messenger ribonucleoprotein complexes that are
associated with polyribosomes [96]. Because of this association, FMRP is implicated in translational
repression [97,98]. Translational repression in neurons is very important because of cell architecture.
Neurons have a cell body with extensive dendritic arbors and axonal projections. Proteins are translated
both in cell bodies and in dendritic spines [99–102]. Translation in dendritic spines is generally
activity dependent [100,102,103]. Several mRNAs have been localized in dendritic spines [104].
Although the process of mRNA transport to dendritic spines is not completely understood, mRNAs
are translationally repressed during their transport. Once they have reached their destination, mRNAs
may remain in a repressed state until synaptic stimulation triggers protein translation. Translation
outside of the cell body, locally at the synapse, is particularly important for the maintenance of synaptic
plasticity and synaptic plasticity in response to stimuli that do not involve nuclear events. Recently,
Darnell and colleagues demonstrated that translational repression by FMRP is achieved by stalling
ribosomal translocation [97]. It is thus understandable that the loss of FMRP function results in
defects of activity-dependent protein synthesis in dendritic spines, which leads to changes in synaptic
plasticity [98].
4. RNA-Binding Proteins and Cancer
Cancer is a heterogeneous disease, and we have no clear understanding of the etiology of
different tumors. Traditionally, it is believed that the development of cancer is associated with
mutations, transcriptional dysfunction and signal pathways gone awry. However, as we gain a greater
understanding of post-transcriptional regulation of gene expression, we realize that post-transcriptional
events contribute to cell proliferation, differentiation, apoptosis and angiogenesis—all processes that
modulate the development and progression of cancer [105]. RNA-binding proteins regulate all aspects
of post-transcriptional gene expression of tumor expressers and oncogenes. It is therefore not surprising
that RBPs play an important role in cancer. A recent study by Kechavarzi and Janga explored the
expression pattern of RBPs in human cancers. They found at least 30 RBPs were upregulated in
two-thirds of all the cancers examined [106]. Here, we focus on some RBPs that are important in
cancer and participate in alternate splicing and protein translation. The protein, Src-associated in
mitosis (Sam 68), is a member of the STAR (Signal Transduction and Activation) family of RBPs
and is important in cellular differentiation and proliferation [76]. Sam 68 is overexpressed in breast
and prostate cancer [107,108]. It is a predominantly nuclear protein involved in alternate splicing
of cancer related mRNAs. For instance, CD 44 mRNA encodes a cell surface glycoprotein involved
in cell-cell and cell-matrix adhesion in cancer cells [109]. Sam 68 regulates alternate splicing of CD
44 pre-mRNA generating more than 20 isoforms encoding for extracellular domains implicated in
cancer development [109]. Cyclin D1 is a proto-oncogene involved in cell-cycle progression. Given
its role in cell proliferation, it is tightly regulated. Overexpression of cyclin D1 is correlated with the
development and progression of cancer [110]. Cyclin D1 has two isoforms D1a and D1b, generated
by alternate splicing of exon 4. Both isoforms are frequently upregulated in cancers. However, out of
the two, D1b isoform exhibits greater oncogenic properties. Interestingly, Sam 68 is also involved in
splicing of cyclin D1 and promotes expression of cyclin D1b isoform [111].
The Hu family of RBPs is another example involved in the development of cancer. Of the Hu
family of proteins, HuR is the one that is most frequently associated with the development of different
cancers including breast, pancreatic, prostate, lung and ovarian cancer [112]. In a resting state, HuR is
predominantly localized in the nucleus but translocates to the cytoplasm following post-translational
modification. Once in the cytoplasm, HuR binds to mRNAs, harboring ARE sequences in their 3'-UTRs,
resulting in stabilization of target mRNAs with an increase in half-lives of the respective mRNAs.
Targets of HuR include Bcl2, CoXII, VEGF, certain kinases, and cyclins—all these target mRNAs are
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involved in cellular growth and proliferation [83]. An increase in half-life of these mRNAs can disrupt
the tightly regulated homeostasis of cell proliferation, leading to the development of cancer.
Translation control is a critical constituent of cancer development and progression. During the
multistep process of protein translation, the translation factor elF4E binds to the 7-methyl guanosine cap
structure at the end of mRNAs, providing a critical interface for the recruitment of the 40S ribosomal
subunit and other translation factors [113]. Expression of elF4E is controlled at multiple levels, and
its increased activity has been implicated in different cancers [113]. It is interesting to note that
increased expression of elF4E is not associated with a global increase in protein synthesis but appears
to promote translation of mRNAs involved in oncogenesis. Such mRNAs have longer 5' untranslated
regions with higher GC content, resulting in more complex hairpin structure formation—one of
the mechanisms that provide control over the protein expression of cancer promoting mRNAs. By
increasing the expression of elF4E, translation of these subsets of mRNAs may be facilitated, allowing
for their selective activation, and thereby promoting tumor formation and progression. From the above
highlights of RBPs role in cancer, it is clear that these proteins are powerful players in the development
and progression of cancer. However, what is not clear at this time is whether alterations in expression
of RBPs are a cause or a consequence of cancer.
5. Approaches to Detection of RBPs
Traditionally, in vitro methods have been utilized to detect RNA-protein interactions, and these
methods remain in vogue. EMSA has been employed extensively in past years and has yielded
invaluable information. In this assay, radiolabeled RNA was incubated with the source of RBP
(purified protein or cell lysate or microsomes or membrane free cytosol), and the resulting complex
was electrophoresed on a non-denaturing polyacrylamide gel and radiolabeled bands were visualized
by exposure to X-ray film or PhosphorImager. Non-specific RNA-protein interaction was prevented
by the incubation of RNA and protein source in the presence of tRNA and/or heparin. The principle
behind this technique is the observation that naked RNA has certain mobility on gels, but its mobility
is retarded upon binding to proteins. To confirm the specificity of the RNA protein interactions, an
excess of unlabeled competitor RNA is added to the reaction mix, and this obliterates the formation of
RNA-protein complex. To confirm the presence of a specific protein in the RNA protein complex, gel
super shift assays can be performed. These assays were performed as in EMSA, except for the addition
of specific antibody to the protein of interest. Formation of RNA-protein-antibody complex further
slows down the migration of complex on a gel. Once the interaction between a specific mRNA and a
RBP is established, immune-RT/PCR can be employed to confirm the RNA-protein interactions [38].
Briefly, the RBP of interest was immunoprecipitated following which RNA was extracted from the
precipitate, and the RNA of interest was amplified using gene specific primers. Another widely used
technique in RNA biology is the conventional UV-cross link analysis. This analytical technique takes
advantage of the ability of short-wave ultraviolet light (254 nm) to activate nucleotide bases (e.g., uracil
and to a lesser degree other nucleotides) to covalently bind to specific amino acids such as Cys, Lys, Trp
and Tyr in proteins [114,115]. In this assay, the protein lysate and radiolabeled RNA were incubated to
allow complex formation. The reaction mix was then UV-irradiated and treated with ribonucleases
to digest unbound RNA. UV irradiation will covalently link RNA to proteins, but protein-protein
interactions are not affected. The protein complex was subsequently resolved on SDS-PAGE. Gels were
dried and the radiolabeled RNA-protein complexes were visualized as in EMSA. As opposed to EMSA
where one can only document the ability of proteins to bind to a specific RNA, UV-cross link analysis
yields information on the number of RBPs binding to a specific RNA or RNA fragment containing
cis-acting region. The size of RBPs binding to RNA can be determined by northwestern analysis. In this
technique, protein lysates are separated on SDS-PAGE and proteins are re-folded and then transferred
to a support membrane such as nitrocellulose membrane. Proteins transferred to membrane were
probed with radiolabeled RNA. Non-specifically bound RNA was washed off and the membrane was
exposed to X-ray film to reveal the number of proteins highlighted by RNA. The molecular size of
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proteins was extrapolated from the standard molecular weight marker proteins separated along with
protein samples on the gel.
The aforementioned in vitro techniques continue to be powerful tools in the RNA field. To detect
RNA-protein interactions in vivo, Darnell et al. developed the cross-linking and immunoprecipitation
(CLIP) method [116]. A distinct advantage of this method is the cross-linking of RNA-proteins in live
cells and/or tissue preserving native associations in the absence of salt and ionic components that
need to be optimized in in vitro assays. Another advantage of this technique is that one can identify
target RNAs of one RBP. The CLIP procedure was comprised of a number of steps that we have briefly
summarized here. For a detailed protocol, the reader is referred to the original publication [116]. In
short, after the tissue or cells were UV-cross linked, lysate was prepared, which was treated with
nucleases to trim the cross-linked RNA to 50–100 nucleotide size. The lysate was cleared of ribosomes
and incubated with beads coupled to the antibody against the RBP of interest. RNA-protein complexes
are partially purified by immunoprecipitation, and non-covalently associated RNA was removed by
SDS-PAGE. The purified RNA protein complexes were treated with proteinase K to remove proteins
but leave RNA, which was abundant enough to perform RNA linker ligation, RT/PCR amplification
and sequencing. The resultant short (70–100 nucleotides) RNA CLIP “tags”, which represent native
RBP binding sites, were able to be database-matched to identify the targets of an RBP. This technique
allowed Darnell et al. to identify 34 targets of NOVA in the brain [116].
With the advent of high-throughput sequencing, it was then possible to map RNA-binding
sites even more comprehensively. Using such a platform, millions of unique RNA tags were able to
be identified and mapped back to the genome yielding transcriptome-wide RNA-protein binding
maps. To further refine the CLIP protocol, Darnell et al. replaced the conventional Sanger sequencing
method employed in CLIP with high-throughput sequencing (HITS-CLIP) [117]. This method allowed
investigators to generate a transcriptome-wide understanding of NOVA-RNA regulation.
6. Computational Methods
RBPs interact with mRNA via a number of RNA recognition motifs or RNA-binding domains [7].
A large number of proteins have been predicted to serve as RBPs using these sets of RNA recognition
motifs (http://rbpdb.ccbr.utoronto.ca/) [118]. In Caenorhabditis elegans, as many as 887 genes may
encode for RBPs [119] and, in Saccharomyces cerevisiae, approximately 600 transcripts encode for putative
RBPs [120]. As our knowledge on RBPs expands, it is becoming apparent that many RBPs do not
harbor conventional or previously identified RNA recognition motifs. For instance, the novel GluN1
mRNA-binding protein, GIIβ does not contain a known RNA recognition motif, and conventional
methods were employed in its identification as a RBP [38]. Computational methods can serve as
powerful complementary approaches to identify RBPs. These methods for post-transcriptional analyses
have recently gained importance as declining costs of next-generation sequencing have made global
approaches more affordable. Some of the high-throughput assays currently employed by RNA
biologists to study post-transcriptional regulation are CLIP, HITS-CLIP, PAR-CLIP and iCLIP [17]. The
utility and advantages, as well as the disadvantages, of these approaches have been described [121].
In general, these techniques involve in vitro or in vivo cross-linking of RNA and proteins, digestion
of unbound RNA, immunoprecipitation using an antibody to a RBP of interest, reverse transcription,
PCR amplification, and high-throughput sequencing. High-throughput sequencing data is typically
uploaded onto public databases such as the Gene Expression Omnibus (GEO from NCBI) and
ArrayExpress (from EBI), and three recently developed databases for CLIP-seq: CLIPZ, doRiNA,
and starbase. As a next step, using computational methods, such as Bowtie, RMAP, Novoalign, and
TopHat, the “short reads” (sequencing data sets) are aligned to a reference sequence (transcriptome
and genome) while eliminating technical sequencing errors and true genetic variations. Once the
“short reads” are aligned to the reference sequence, several restrictions are applied to filter the noise
in processing the data further to detect a cluster of reads. A cluster of reads is a group of reads that
has some sequence overlap. Usually, reads with a length above a certain threshold are considered for
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further analysis to detect RBP binding sites. RBP binding site detection is a challenging process. Several
computational methods such as WavClusteR, PARalyzer, Piranha, PIPE-CLIP, dCLIP, and GraphProt
have been developed and utilized to detect RBP binding sites while minimizing the detection of
false positives and background. Computational methods such Piranha and RIP-seeker have been
developed specifically for peak calling [17]. Peak calling simply refers to a RNA sequence that
interacts with a RNA-binding protein. The identification of peak calling is a crucial step that follows
the alignment of the short-sequence reads to a reference genome. Piranha is mainly a peak-calling
algorithm that provides a way to detect differential binding across different conditions. PIPE-CLIP is
a Galaxy-based comprehensive online tool for CLIP-seq data analyses. It provides data processing
but also statistical analyses [122]. PARalyzer is another popular peak calling algorithm for PAR-CLIP
datasets only. Finally, motif recognition algorithms are used to identify motifs recognized by RBP.
Algorithms such as MEMEris, PhyloGibbs, RNAcontext, and RNAmotifs identify motifs at the RNA
level, while MEME, cERMIT, GLAM2, and MatrixREDUCE were developed to identify motif at the
DNA level. Lastly, the identified RBP motif is analyzed using mCarts or GraphProt to predict candidate
RBP binding sites within the same organism. A summary of computational methods employed for
high-throughput RNA-protein interaction data has been provided by Bahrami-Samani et al. [17]. In
addition, a recent review by Janga has summarized different computational and experimental methods
employed to identify novel RBP and their targets [123]. Because of increasing use of genome-wide
analyses and evolving computational tools, a staggering amount of data is being generated. Of course,
such data sets are prone to detecting false positives due to: (1) replacement of non-covalent bonds
by UV-induced covalent bonds that cannot be eliminated by stringent washing; (2) ultrasensitive
nature of high-throughput sequencing; and lastly, (3) development of tools that fits one scientist’s
needs and hence is not a universal analysis tool. Our next challenge will be to develop and refine
bio-informatics tools that can be used easily by all researchers. However, perhaps the most crucial issue
to be considered is the actual biological validation of the data. This important task is often laborious
and time-consuming but rewarding.
7. Conclusions and Future Directions
The search for better and more selective drugs for the treatment of cancer, infections and many
other pathologies is an ongoing and challenging effort. New discoveries in the RNA field open
up opportunities for RNA-binding proteins to serve as therapeutic agents. When we have a better
understanding of the targets of RNA-binding proteins, it will be possible to modulate gene expression
at several post-transcriptional levels. Tailored RNA-binding proteins can be used to alter expression of
single genes or even complete gene families whose transcripts share common “cis acting elements”.
When efficient gene delivery systems become a reality RNA-binding proteins may become the “drugs”
of choice for customized therapies.
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